4MOVING-BIOTECH
4Moving Biotech (4MB), a clinical-stage subsidiary of 4P-Pharma specializing in immuno-inflammation and osteoarthritis, is pleased to announce the appointment of Luc Boblet as Chief Executive Officer. The company, having successfully completed its Phase I clinical trial and a preparatory in silico Phase 2 analysis, looks to Luc Boblet's seasoned expertise in biotech entrepreneurship and strategic development to guide the forthcoming stages of clinical proof of concept and early market access.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240701233556/en/
Luc Boblet, CEO OF 4Moving Biotech (Photo: Business Wire)
Luc Boblet, a biotech entrepreneur with two decades of experience, joins 4MB following his tenure at Egle Therapeutics, where his leadership was essential in advancing novel immunotherapies and securing a robust Series A funding backed by a big pharma strategic alliance. His previous roles included founding and leading companies such as H-IMMUNE - acquired by HiFiBIO - and Pathoquest, where he excelled in driving innovation, closing fundraising and forging strategic partnerships as instrumental catalyst of growth.
"Luc's appointment comes at a turning point for 4Moving Biotech as we have concluded a milestone Phase I trial for our leading drug candidate and are advancing strategic discussions with the FDA, toward potential accelerated approval" said Revital Rattenbach, founder and CEO of 4P-Pharma and co-founder of 4Moving. "His track record in steering biotech ventures and his strategic approach to partnerships will be invaluable as we advance our clinical programs and explore opportunities for pharma co-development and partnership."
As CEO of 4Moving Biotech, Luc Boblet's immediate focus will be on overseeing the design and implementation of the development strategy for the upcoming Phase II clinical trials, as well as cultivating partnerships that align with the company's vision for growth and patient access to innovative treatments.
Luc Boblet, CEO of 4Moving Biotech said: "The opportunity to lead 4Moving Biotech at this juncture is one that is aligned with my commitment to bringing pioneering therapies for untreated severe diseases. The company's progress in drug development and the potential to significantly improve patient outcomes in osteoarthritis is a strong foundation for future success. I am looking forward to applying my experience in corporate strategy business development to deliver our value proposal and establish meaningful partnerships."
About 4Moving Biotech
4Moving Biotech, a subsidiary of 4P-Pharma, is dedicated to developing advanced first in class therapies in the field of immuno-inflammation and osteoarthritis. With a commitment to improving patient care, 4MB is actively engaged in the clinical development of novel treatments poised to enhance quality of life for patients worldwide.
Biography of Luc Boblet, CEO of 4Moving Biotech.
Luc Boblet is a serial biotech entrepreneur with 20 years of experience in entrepreneurship, business development, corporate finance and early drug development. Luc is coming from Egle Therapeutics, spin out of Institut Curie dedicated to developing novel Regulatory T-cells based immunotherapies for oncology and autoimmune diseases, he has co-founded in early 2020. As a founding CEO, he built Egle Tx with a vision to become a game changer in the field of Tregs immunomodulation catalyzed by strategic alliance with Takeda Pharmaceutical and backed by 45M€ Series A from a high-quality syndicate of renowned international investors. Before creating Egle Tx, Luc co-founded and ran H-IMMUNE, start-up spun out of French Nuclear Agency (CEA), developing novel anti-check-point immunotherapies against T-effector and Tregs for oncology. He paved H-IMMUNE corporate path through partnerships with Pierre Fabre Laboratories and Norther Biologics and have exited H-IMMUNE through an acquisition by HiFiBIO in 2018. Before co-founding H-IMMUNE, Luc co-founded and ran Pathoquest, a start-up company spun out of Institute Pasteur, which develops disruptive unbiased NGS-based diagnostics in the field of infectious diseases. Under his guidance, Pathoquest raised two VC-backed rounds of financing, closed strategic collaborations and corporate partnerships with leading pharma companies (CERBA Laboratories and Covance), and launched several clinicals trials in France and the U.S.
From 2011 to 2015, he served on the board of directors of the BioAster Technological Research Institute.
He started his career in technology transfer, consulting in finance and business development for toxicogenomics R&D. Luc Boblet holds a biotech engineering degree, master’s degree in Virology and has been trained as a PhD in Virology from University Paris VII.
About 4Moving Biotech
Incorporated in mid 2020 as a spin-off of 4P-Pharma, 4Moving Biotech is a clinical stage biotechnology company dedicated to the development of the Disease-Modifying Osteoarthritis Drug (DMOAD). Its mission is to provide a sustainable therapeutic solution to the significant unmet medical need of osteoarthritis. The company is headquartered at the Pasteur Institute in Lille, France.
Website: https://www.4movingbiotech.com/
LinkedIn: https://fr.linkedin.com/company/4moving-biotech
X: https://twitter.com/4Moving_Biotech
The only version of the 4Moving Biotech press release that is legally binding is the one in its original language. Translations must always be compared to the source text, which will establish precedence. The press release text resulting from a translation should not be considered official in any way.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240701233556/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
REPLY: The Board of Directors Approves the Quarterly Financial Report as of 30 September 202513.11.2025 13:23:00 CET | Press release
All economic indicators have substantially improved:Consolidated turnover of €1,819.8 million (1,669.6 as at 30 September 2024)EBITDA of €335.5 million (275.5 as at 30 September 2024)EBIT of €281.0 million (224.2 as at 30 September 2024)Pre-tax profit of €268.1 million (216.0 as at 30 September 2024)Positive Net Financial Position of €423.1 million. Today, the Board of Directors of Reply [EXM, STAR: REY] approved the results as at 30 September 2025. The Group's consolidated turnover in the first nine months of the year reached €1,819.8 million, an increase of 9.0% compared to €1,669.6 million recorded on 30 September 2024. The indicators for the period are positive. Consolidated EBITDA was €335.5 million, equal to 18.4% of the consolidated revenues. As of September 2024 EBITDA was €275.5 million. EBIT, from January to September, reached €281.0 million, equal to 15.4% of the consolidated revenues. The corresponding 2024 figure was €224.2 million. Pre-tax profit, from January to Septembe
Hilton Again Named No. 1 World’s Best Workplace13.11.2025 13:16:00 CET | Press release
New Data Shows Why the Best Place to Work is Also the Best Place to Stay: Hilton Study Links Consumer Preference to Employee Happiness Newly commissioned Hilton research shows nearly 80% of U.S. consumers say that companies that take good care of their employees provide better products and services. Nearly 90% of U.S. consumers say that taking care of employees is especially important for travel and hospitality brands. Three in four U.S. consumers say they are more likely to recommend doing business with a company that is known to treat its employees well. More than 90% of team members say Hilton is a Great Place to Work where they can learn and grow. Once again named the No. 1 World’s Best Workplace by Fortune and Great Place to Work,Hilton (NYSE: HLT) today is releasing findings of a newly commissioned study linking the role of employee experience to consumer purchasing decisions and service experiences. This press release features multimedia. View the full release here: https://www.
Prime Minister Oversees Signing of 55 Pacts in Major Push for Egypt’s Offshoring Industry13.11.2025 13:08:00 CET | Press release
ITIDA signed agreements with multinational and local companies, boosting a knowledge-based economy and a future-ready workforce.Agreements create over 70,000 new offshoring jobs, strengthening Egypt’s role as a global delivery powerhouse. Under the patronage of H.E. Dr. Mostafa Madbouly, Prime Minister of Egypt, the Information Technology Industry Development Agency (ITIDA) announced the signing of 55 strategic agreements with leading multinational and local technology companies in offshoring and IT-enabled services, including Teleperformance, Accenture, Deloitte, VOIS, Luxoft, RSA, and Capgemini. The ceremony, attended by H.E. Dr. Mostafa Madbouly and Dr. Amr Talaat, Minister of Communications and Information Technology, gathered senior representatives, highlighting Egypt’s growing role as a hub for global business services supported by skilled talent, robust infrastructure, and cost competitiveness. This press release features multimedia. View the full release here: https://www.busin
RSA Announces New Solution to Enhance Security for Microsoft Entra ID13.11.2025 13:00:00 CET | Press release
RSA, the security-first identity leader, announced today that RSA® ID Plus for Microsoft, a new solution category that provides an enhanced security layer for Microsoft Entra ID, is now generally available. Now on the Microsoft Azure Marketplace, the first product, RSA ID Plus M1, includes key capabilities that defend organizations from emerging attacks and help them maintain operational continuity in both Microsoft and non-Microsoft environments. RSA ID Plus for Microsoft M1: Protects resources within and beyond the Microsoft ecosystem: RSA ID Plus provides total coverage for legacy, OT, Microsoft, and non-Microsoft environments, bringing modern MFA and passwordless to data centers, mainframes, macOS, AD-joined devices, Entra-joined PCs and servers (including older OS versions), and other web servers and critical infrastructure that Entra alone can’t reach. Ensures mission-critical resources are always available and always protected: RSA’s unique Hybrid HA architecture and offline cap
Dubai Electricity and Water Authority PJSC Announces Record Breaking Revenue of AED 25 Billion and Operating Profit of AED 8.3 billion for the First Nine Months Ending Sept 202513.11.2025 11:19:00 CET | Press release
Dubai Electricity and Water Authority PJSC: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251112162153/en/ HE Saeed Mohammed Al Tayer, MD & CEO of DEWA (Photo: AETOSWire) Record nine months of 2025 Results AED 24.9 billion AED 13.1 billion AED 8.3 billion AED 6.8 billion +5.9% YoY +11.9% YoY +21.5% YoY +24.8% YoY 9 months of 2025 Revenue 9 months of 2025 EBITDA 9 months of 2025 Operating Profit 9 months of 2025 Profit After Tax * figures are rounded Record Q3 2025 Results AED 10.3 billion AED 6.2 billion AED 4.6 billion AED 3.9 billion +4.5% YoY +20.4% YoY +29.8% YoY +35% YoY Q3, 2025 Revenue Q3, 2025 EBITDA Q3, 2025 Operating Profit Q3, 2025 Profit After Tax * figures are rounded Dubai Electricity and Water Authority PJSC (ISIN: AED001801011) (Symbol: DEWA), the Emirate of Dubai’s exclusive electricity and water services provider, which is listed on the Dubai Financial Market (DFM), today reported its consolidated financia
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom